Max Signaevsky

Dr. Signaevsky’s research interests in Neuroscience focus on developing an Artificial Intelligence/Machine Learning platform for diagnosis and quantification of neurodegenerative disease as well as developing an interface between the brain, its neural network, and computing devices.

Dr. Signaevsky has received his medical (MD) and research (Ph.D.) training in Russia and The Netherlands and moved to North America to pursue his life-long goals of solving fundamental medical problems. His first foray into the clinical research involved exploratory projects in cancer research, which led to a series of papers and patents. Later, Dr. Signaevsky successfully completed a five-year neuropathology residency at the University of British Columbia. It was followed by a fellowship in neurodegenerative diseases, and subsequently, by a fellowship in Brain Banking at the Icahn School of Medicine at Mount Sinai in New York, NY.

Dr. Signaevsky is also a recipient of a NIH/NIA Career Development in the Neuropathology of AD Award. He has co-founded NeuroSilica, Inc. in 2015, to lead the R&D of brain-computer interface.

Arturas Vaitaitis Advisor